Rebate Reprieve For Generics And Biosimilars Added To Build Back Better Act
Generics Facing Shortages And Biosimilars Are Now Exempt From Rebate Scheme
The Build Back Better Act has been updated to exempt generics experiencing or at risk of shortage from its planned inflation rebates, as well as biosimilars. But the US Association for Accessible Medicines has called for further changes to the proposed bill to protect off-patent drugs.
